Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors

Author： Wakui Hiroshi   Yamamoto Noboru   Nakamichi Shinji   Tamura Yousuke   Nokihara Hiroshi   Yamada Yasuhide   Tamura Tomohide  

Publisher： Springer Publishing Company

ISSN： 0344-5704

Source： Cancer Chemotherapy and Pharmacology, Vol.73, Iss.3, 2014-03, pp. : 511-516

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors

By Doi Toshihiko   Ohtsu Atsushi   Fuse Nozomu   Yoshino Takayuki   Tahara Makoto   Shibayama Kazuhiro   Takubo Takatoshi   Weinreich David  

Cancer Chemotherapy and Pharmacology, Vol. 71, Iss. 1, 2013-01 ,pp. : 227-235

Springer Publishing Company

Access to resources Recommend Favorite

Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors

By Macaulay V. M.   Middleton M. R.   Protheroe A. S.   Tolcher A.   Dieras V.   Sessa C.   Bahleda R.   Blay J.-Y.   LoRusso P.   Mery-Mignard D.   Soria J.-C.  

Annals of Oncology, Vol. 24, Iss. 3, 2013-03 ,pp. : 784-791

Oxford University Press

Access to resources Recommend Favorite

A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors

By Chiorean E.   Sweeney Christopher   Youssoufian Hagop   Qin Amy   Dontabhaktuni Aruna   Loizos Nick   Nippgen Johannes   Amato Robert  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 595-604

Springer Publishing Company

Access to resources Recommend Favorite

Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors

By Fujisaka Yasuhito   Yamada Yasuhide   Yamamoto Noboru   Shimizu Toshio   Fujiwara Yutaka   Yamada Kazuhiko   Tamura Tomohide   Watanabe Hiroyuki   Sun Yu-Nien   Bass Michael   Seki Mitsuo  

Cancer Chemotherapy and Pharmacology, Vol. 66, Iss. 5, 2010-10 ,pp. : 935-943

Springer Publishing Company

Access to resources Recommend Favorite

An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors

By Murakami H.   Kurata T.   Onozawa Y.   Watanabe J.   Ono A.   Takahashi T.   Yamamoto N.   Fujisaka Y.   Kiyota H.   Hayashi H.   Tanaka K.   Nakagawa K.   Kuroda S.  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 623-630

Springer Publishing Company

Access to resources Recommend Favorite